Aspen Neuroscience and Bambusa Therapeutics each aim for $135 million IPOs
Aspen Neuroscience announced plans to raise about $135 million through an initial public offering, proposing to sell roughly 9.38 million shares.
Bambusa Therapeutics also filed for an IPO targeting the same $135 million amount, positioning itself alongside Aspen in the upcoming market offerings.
The announcements come amid broader industry activity, including competitive developments between AstraZeneca and Takeda on gastric cancer antibody-drug conjugates and updates from companies such as Hutchmed, Johnson & Johnson, Jazz Pharmaceuticals, Novartis, Roche and Oruka Therapeutics.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Aspen, Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCs”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that